Published online before print January 20, 2005, doi: 10.1161/01.ATV.0000156877.94472.a5
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Special Article |
Leukocytosis and Ischemic Vascular Disease Morbidity and Mortality
Is It Time to Intervene?
From the The Rockefeller University, New York, NY.
Correspondence to Barry S. Coller, The Rockefeller University, 1230 York Ave, New York, NY 10021. E-mail collerb{at}rockefeller.edu
The association between leukocytosis and increased morbidity and mortality of ischemic vascular disease has been observed for more than half a century, and recent studies in >350 000 patients confirm the robustness of the association and the dramatically higher relative and absolute acute and chronic mortality rates in patients with high versus low leukocyte counts. Although there is reason to believe that the association is not causal (that is, that leukocytosis is simply a marker of inflammation), there is also reason to believe that the leukocytosis directly enhances acute thrombosis and chronic atherosclerosis. Leukocytosis also is associated with poor prognosis and vaso-occlusive events in patients with sickle cell disease, and experimental data suggest a direct role for leukocytes in microvascular obstruction. The only way to test whether leukocytes contribute directly to poor outcome in ischemic cardiovascular disease is to assess the effect of modifying leukocyte function or number. Because selective blockade of leukocyte integrin 
Mß2 and P-selectin have thus far been disappointing as therapeutic strategies in human cardiovascular and cerebrovascular disease, I discuss the potential risks and benefits of short-term treatment with hydroxyurea to decrease the leukocyte count in select populations of patients at the highest risk of short-term death.
This article reviews the epidemiological evidence of an association between leukocytosis and increased morbidity and mortality from ischemic vascular disease, focusing on whether the data are consistent with a causal role for leukocytes in vascular events. It then discusses whether the existing data justify selectively entering to lower the leukocyte count.
Key Words: leukocytes • neutrophils • myocardial infarction • thrombosis
This article has been cited by other articles:
 |
|
 |
|
  A. Carobbio, E. Antonioli, P. Guglielmelli, A. M. Vannucchi, F. Delaini, V. Guerini, G. Finazzi, A. Rambaldi, and T. Barbui Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia J. Clin. Oncol., June 1, 2008; 26(16): 2732 - 2736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Tsai, L. J. Beilin, I. B. Puddey, K. D. Croft, and A. Barden Impaired ex Vivo Leukotriene B4 Production Characterizes the Metabolic Syndrome and Is Improved after Weight Reduction J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4747 - 4752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Cavusoglu, E. Kornecki, M. B. Sobocka, A. Babinska, Y. H. Ehrlich, V. Chopra, S. Yanamadala, C. Ruwende, M. O. Salifu, L. T. Clark, et al. Association of Plasma Levels of F11 Receptor/Junctional Adhesion Molecule-A (F11R/JAM-A) With Human Atherosclerosis J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1768 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Rogowski, I Shapira, A Shirom, S Melamed, S Toker, and S Berliner Heart rate and microinflammation in men: a relevant atherothrombotic link Heart, August 1, 2007; 93(8): 940 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. C. Raffel, G. J. Tearney, D. D. Gauthier, E. F. Halpern, B. E. Bouma, and I.-K. Jang Relationship Between a Systemic Inflammatory Marker, Plaque Inflammation, and Plaque Characteristics Determined by Intravascular Optical Coherence Tomography Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1820 - 1827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ruggiero, E. J. Metter, A. Cherubini, M. Maggio, R. Sen, S. S. Najjar, G. B. Windham, A. Ble, U. Senin, and L. Ferrucci White Blood Cell Count and Mortality in the Baltimore Longitudinal Study of Aging J. Am. Coll. Cardiol., May 8, 2007; 49(18): 1841 - 1850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Landolfi, L. Di Gennaro, T. Barbui, V. De Stefano, G. Finazzi, R. Marfisi, G. Tognoni, R. Marchioli, and for the European Collaboration on Low-Dose Aspirin Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera Blood, March 15, 2007; 109(6): 2446 - 2452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Carobbio, G. Finazzi, V. Guerini, O. Spinelli, F. Delaini, R. Marchioli, G. Borrelli, A. Rambaldi, and T. Barbui Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status Blood, March 15, 2007; 109(6): 2310 - 2313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Heptinstall, J. R. Glenn, A. Johnson, B. Myers, A. E. White, and L. Zhao Leukocytosis, Vascular Disease, and Adenine Nucleotide Metabolism Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): e22 - e23. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Palmerini, A. Marzocchi, C. Marrozzini, P. Ortolani, F. Saia, L. Bacchi-Reggiani, S. Virzi, S. Gianstefani, and A. Branzi Preprocedural Levels of C-Reactive Protein and Leukocyte Counts Predict 9-Month Mortality After Coronary Angioplasty for the Treatment of Unprotected Left Main Coronary Artery Stenosis Circulation, October 11, 2005; 112(15): 2332 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nasir, E. Guallar, A. Navas-Acien, M. H. Criqui, and J. A.C. Lima Relationship of Monocyte Count and Peripheral Arterial Disease: Results From the National Health and Nutrition Examination Survey 1999-2002 Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1966 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Kaski, P. Avanzas, R. Arroyo-Espliguero, and B. S. Coller Neutrophil Count and Complex Lesions in Patients With Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): e112 - e112. [Full Text] [PDF]
|
|